Dr Rishabh Jain· @DrRishabhOnco · X·· 1 天前评分70
正文 · 机器翻译
🚨 SAFFRON：osimertinib 耐药后实现双重生存获益！
在 #ESMO26 期间于 NEJM 同步发表！
III期 | EGFR 突变、MET 高表达 NSCLC
osimertinib + savolitinib 对比化疗：
📈 PFS：7.6 对 5.4 个月（HR 0.55；p<0.001）
🔥 OS：17.8 对 12.9 个月（HR 0.68；p=0.01）
🎯 ORR：51% 对 27%
💡 结论：MET 驱动的耐药具有可干预性。osimertinib 进展后进行再活检，可能带来一种能够改善生存的靶向治疗选择！
@myesmo @ESMO_open @NEJM @ASCO @oncoalert @nicogirardcurie
完整论文链接见下方评论 ⬇️
20 浏览 · 0 赞 · 0 转发 · 1 回复
🚨 SAFFRON Phase III: Targeted therapy beats chemotherapy AND improves survival! In EGFR-mutant, MET-overexpressed/amplified NSCLC progressing after osimertinib: Osimertinib + savolitinib vs platinum–pemetrexed (n=338) 📊 PFS: 7.6 vs 5.4 months (HR 0.55; p<0.001) 🔥 OS: 17.8 vs 12.9 months (HR 0.68; p=0.010) ⚠️ Grade ≥3 treatment-related AEs: 40% vs 52%. Verdict: A new biomarker-selected, chemotherapy-free option with demonstrated OS benefit after osimertinib resistance. #ESMO26 #LungCancer @my_esmo @ESMO_open @ASCO @oncoalert在 X 查看被引用的帖子
帖内回复
- Dr Rishabh Jain@DrRishabhOnco
Osimertinib–Savolitinib in Advanced NSCLC after Progression during EGFR-TKI Therapy | New England Journal of Medicine https://www.nejm.org/doi/full/10.1056/NEJMoa2611335?query=featured_home
来源：Dr Rishabh Jain · x.com